Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 18/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29258844 | 0.87 | P2RY12 (0.65) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL30999839 | 0.87 | P2RY12 (0.65) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL4115190 | 0.85 | P2RY12 (0.70) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL4737910 | 0.84 | P2RY12 (0.80) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL4740662 | 0.83 | P2RY12 (0.59) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL3221673 | 0.83 | P2RY12 (0.69) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL18994740 | 0.82 | P2RY12 (0.50) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL3934955 | 0.81 | P2RY12 (0.63) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| Hydrochloric Acid SCHEMBL4105657 | 0.81 | P2RY12 (0.62) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL4740864 | 0.80 | P2RY12 (0.56) | P2RY12CYP2C9CYP3A4CHRM2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176827-A1 | New Pyridine Analogues VII 543 | ASTRAZENECA AB (SE) | 2008-07-24 | — | — | US | disclosed |
| WO-2008085118-A1 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS. | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176827-A1 | New Pyridine Analogues VII 543 | P2RY12, P2RY11, P2RY4 | P2RY12 1/4885CYP2C9 387/4885CYP3A4 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.